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'Anyone who isn't confused doesn't really understand the situation.'
Ed Murrow, 1969
Summary
Three areas of clinical research in breast cancer treatment led to
news breaking presentations at the American Society of Clin-
ical Oncology (ASCO) meeting, 1998, in Los Angeles. All three
subjects represent important advances in cancer medicine.
Prevention: Two related drugs, tamoxifen and raloxifene,
were found in placebo controlled trials to significantly reduce
the incidence of breast cancer for women at increased risk of
developing the disease. Patterns of relapse showed that the
reduced rate of breast cancer was exclusively observed for
tumors expressing estrogen receptors, while the rate of tumors
classified as estrogen-receptor negative was similar for the
treatment and the control groups. This may indicate that the
observed reduction in breast cancer incidence is due to a
treatment effect on occult disease rather than its prevention.
We certainly have no adequate information on mortality pre-
vention.
Adjuvant therapies: Taxol given every three weeks for four
courses following an adjuvant treatment with four courses of
doxorubicin and cyclophosphamide (AC) combination was
found to be superior to not adding treatment after the four
courses of AC in a trial involving 3170 patients. At 22 months
of median follow-up, the quoted F-values were P - 0.0077 for
disease-free survival and P = 0.039 for overall survival, but
these did not cross the prospectively defined interim analysis
boundaries for statistical significance at the 0.05 level. The
difference was observed early during follow-up, and was ex-
clusively seen in the 40% of patients who had ER-negative
primaries and, therefore, did not receive tamoxifen following
chemotherapy. One may thus argue that the early difference
observed was primarily due to differences in the duration of the
treatment regimens in the two groups and the early entry into
the trial of patients with particularly aggressive neoplasia
(e.g., ER-negative primaries) who would have benefited from a
longer duration treatment.
Treatment of advanced disease: The use of monoclonal anti-
bodies to c-erb-B2 was found to induce responses in metastatic
breast cancer. Patients with tumors expressing c-erb-B2 re-
sponded to weekly infusions of this biological agent. It was
particularly impressive that the response rate for patients
receiving infusion of the monoclonal antibodies together with
the cytotoxics was superior to that with chemotherapy alone in
a randomized trial. It is important to note that only patients
with tumors overexpressing c-erbB-2 (the overall incidence is
about 20%) were tested. It must still be demonstrated that the
effect of these monoclonal antibodies is indeed confined to
cells overexpressing c-erbB-2. Treatment related cardiac tox-
icity remains a problem, and the effects of treatment in various
subsets of patients need to be defined before starting investiga-
tions in the adjuvant setting, which is a clear further objective
of this specific research.
The significant findings from clinical research opened several
new questions, which must be answered before allowing them
to be employed in routine patient care.
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It was important for women, patients, researchers, and
care providers from the oncologic community to have up-
to-date results of recent developments in the treatment of
breast cancer. Presentations at the annual meeting of the
American Society of Clinical Oncology (ASCO) in mid-
May, 1998, in Los Angeles served this purpose well. The
rapid sequence of significant results from clinical re-
search was also reported in the media, announcing
'breakthroughs' in the headlines and quoting more or less
accurately the cautious presentation and commentary of
the investigators. Impressed by the scientific value of the
findings and excited by the opportunity they provide for
a potential improvement in patient care, as well as by the
opportunity to develop further clinical research, we de-
cided to comment upon some of the findings publicly.
SERMs (selective estrogen receptor modulators) for
the prevention of breast cancer
Several weeks and months ago tamoxifen and raloxifene,
respectively, were announced to prevent breast cancer
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[1, 2]. Tamoxifen was studied in 13,388 women who had
an elevated risk of breast cancer and were randomized to
receive the drug or placebo for the duration of five years.
The results of the study appeared first in the lay press
and on the Internet. A significant reduction in invasive
and in situ breast cancer was observed, which motivated
the Data Monitoring Committee for the BCPT Trial
P-01 of the NSABP to advise that women participating
in the trial be informed of the results. The investigators
reported a reduced invasive breast cancer incidence of
45%, 85 cases in the tamoxifen group compared with 154
cases in the placebo group. At the ASCO meeting they
reported that the difference between the two treatment
arms was exclusively confined to the ER-positive tumors,
while no significant difference was observed between
the 34 tumors expressing no or low levels of estrogen
receptor in the tamoxifen group compared to 28 in the
placebo group.
Data on the raloxifene trial were also presented.
Raloxifene was primarily studied for its estrogen-like
activity on bone and lipid metabolism. A large placebo-
controlled randomized trial was conducted in women 60
years old or older who had osteoporotic fracture or
reduced bone mineral density. Its results have been
published [3]. At the ASCO Meeting the breast cancer
incidence was presented showing a significant reduction
of (combined) invasive and in situ breast cancer [2].
Overall, there was a 58% reduction in risk. Also for
raloxifene it was reported that the difference in inci-
dence of breast cancer was entirely confined to the ER-
positive (and PgR-positive) tumors, while the incidence
of ER-negative malignancies was equal in the two treat-
ment groups. We thus conclude, as did Dr. K. Osborne,
in his elegant formal discussion, that the early differ-
ences observed in these two trials are likely to be the
result of a treatment effect of the SERMs on subclinical
existing cancer, considering their known efficacy in
patients with ER-positive tumors. The decision of the
NSABP to stop the trial and to offer tamoxifen to all
patients randomized to the placebo seems justified by
the predefined stopping rule, but may therefore compro-
mise the trials' objective - to assess the preventive value
of the drug. It is in fact unclear whether the patients who
developed an excess of breast cancer in the placebo
group could be 'rescued' by post diagnosis adjuvant
tamoxifen therapy. Now, by receiving tamoxifen instead
of placebo, their risk to develop endocrine-therapy-
responsive tumors will diminish, while their risk to
develop endocrine-therapy-nonresponsive tumors will
remain unchanged. Their risk to have one of the tamox-
ifen-related side effects will increase. Long term results
from the trial will become diluted by the treatment
switch. This pivotal trial of the NSABP and the results
from the raloxifene trial provide, however, a major stim-
ulus for clinical research in the field to move further.
While the IBIS (International Breast cancer Interven-
tion Study) [4] and the Italian [5] trials might still allow
a more efficient answer on the question of prevention
and long-term effects, the NSABP announcement of
further research comparing tamoxifen and raloxifene
(the STAR trial) seems to be an obvious continuation.
Another important line of clinical research in this field is
the possible correlation between c-erbB-2 overexpres-
sion and resistance to tamoxifen.
Adjuvant systemic treatments
Another trial that reported early at the ASCO Meeting
was the Intergroup Trial 0102 led by the CALGB [6].
This randomized trial used a 3 x 2 design to compare
three doses of doxorubicin (60, 75 or 90 mg/m2 by
random allocation) plus cyclophosphamide (600 mg/m2)
given i.v. on day 1 every three weeks for four courses
(AC x4), and to compare Taxol (paclitaxel 175 mg/m2 in
a three-hour infusion every three weeks) for four courses
following AC versus no additional chemotherapy. Thus,
eight courses of adjuvant systemic treatment were com-
pared with four courses of AC (with the same random-
ized dose intensity). The trial accrued 3170 patients and
was reported despite a very short median follow-up of
22 months. The recurrence rate was reduced by 22% and
the death rate by 26% (P = 0.0077 and P = 0.039,
respectively), but the prospectively defined interim anal-
ysis boundaries for statistical significance at the 0.05
level were not crossed. The presented results are shown
in Table 1.
Although the absolute differences in early follow up
are small, they represent substantial proportional reduc-
tions in the risk of relapse and death. One of the con-
clusions formulated by Dr. I. C. Henderson, who pre-
sented the trial, was therefore that the result of this study
demonstrated a significant improvement of adjuvant sys-
temic treatments. While it is likely that the addition of
taxanes to the adjuvant treatment armamentarium will
improve outcome, this trial unfortunately confounded
the addition of a new drug with total adjuvant therapy
duration. The early benefits seen with Taxol were exclu-
sively in patients with ER-negative tumors. These pa-
tients are more likely to benefit from the longer duration
treatment [7]. They were presumably also more likely to
enter this trial early during recruitment because they
had a higher risk of relapse to justify the higher level of
toxicity from both the increasing doses of doxorubicin
and the addition of Taxol. In fact, the two trials showing
convincing and significant improvement of treatment
results as compared to 'classical' CMF were those com-
paring six courses of CMF to more toxic regimens of
cyclophosphamide, anthracycline (either doxorubicin or
epirubicin), and fluorouracil (either CAF or CEF) given
on days 1 and 8 for six courses every four weeks [8, 9].
Table 1 DFS and OS percentages (± s.e.).
AC AC followed by Taxol P- value
DFS at 18 months
OS at 18 months
86% ± 1.2%
95% ± 0.7%
90% ± 1.0%
97% ± 0.6%
0.0077
0.0390
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Thus, the schedule and duration of adjuvant therapies
may play an important role in treating high risk breast
cancer [10], and it is important that future trials testing
the combination of taxanes within such regimens main-
tain designs that do not suffer from further confounding
factors.
The new biology (at last) shows efficacy against
metastatic disease
Results of the two studies on the first therapy engineered
to target a specific protein defect underlying the malig-
nant progression of breast cancer were presented. The
discovery of the amplification of the c-erbB-2 gene, a
member of the epidermal growth factor receptor family,
and the overexpression of its product led to the develop-
ment of a recombinant, humanized monoclonal anti-
body targeted towards the extracellular domain of the
receptor (Herceptin®). The use of this monoclonal
antibody in 222 patients with metastatic breast cancer
expressing c-erbB-2 was found to induce complete re-
sponses in six patients and partial responses in 25
patients (overall response rate (CR + PR) 31 of 222 =
14%; 95% CI: 10%, 19%) [11]. The median duration of
response was 8.4 months. Adverse effects of the antibody
included symptoms such as chills, fever and paleness in a
large proportion of the patients, indicating the multi-
systemic reaction to the drug, probably related to cyto-
kine release. Furthermore, reduction in cardiac ejection
fraction was observed in 10 patients of whom six were
symptomatic and nine had prior anthracyclines.
The other important report at the ASCO Meeting
involved the results of a randomized trial using Hercep-
tin® with doxorubicin-cyclophosphamide (AC) or pa-
clitaxel (T) in 469 patients with metastatic breast cancer
overexpressing c-erbB-2. AC was given as first chemo-
therapy, while paclitaxel was used if the patients had
received prior adjuvant doxorubicin [12]. The trial was
based upon previous investigations in vitro, reported by
the group of Dr. Slamon, describing a phenomenon
called receptor-enhanced chemosensitivity, which, they
predicted, may provide a rationale for more selective
targeting and exploitation of overexpressed growth fac-
tor receptors in cancer cells [13]. Treatment regimens
included the following doses of drugs and schedules:
A = 60 mg/m2, C = 600 mg/m2, T = 175 mg/m2 in a
three-hour infusion, all given every three weeks for six
courses. Herceptin® was given to half of the patients by
random allocation (4 mg/kg loading, then 2 mg/kg i.v.,
once weekly). The results are summarized in Table 2.
Cardiac toxicity was also reported to be frequent in
this trial, especially in the group receiving AC and
Herceptin® (18% of grade 3 and 4). However, the im-
provement in treatment outcome was so impressive that
it might justify evaluation of the combined regimen
(chemotherapy and Herceptin®) in the adjuvant setting,
though perhaps initially only for women at very high-
risk of relapse, whose tumors contain some cells stain-
Table 2. Treatment
ORR %
MRD mos.
TTP mos.
results with
AC + H
52
9.1
and without
T + H
42
11
7.6
Herceptin®.
AC
43
6.5
T
16
4.4
4.6
Abbreviations: AC - doxorubicin-cyclophosphamide; T - paclitaxel;
H - Herceptin®; ORR - overall response rate; MRD - median
response duration; TTP - median time to progression.
ing for c-erbB-2. Another important step is to further
define the target population, which might benefit from
the addition of Herceptin to chemotherapy. It is, there-
fore, essential to verify the degree of overexpression of
c-erbB-2 needed to observe response. Further under-
standing of the clinical relevance and the pathophysio-
logical background for the observed myocardial toxicity
may be a conditio sine qua non for a reasonable continu-
ation of investigations in the adjuvant setting.
It is rare that a Yearly Meeting provides so much new
information with the potential to substantially influence
patient care and future clinical research. This was the
primary reason for summarizing our perception of its
relevance.
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